Home >  News >  Industry >  Pharma News >  Cipla expects elevated...

Cipla expects elevated capital expenditure on automation to continue for three more years

By - Ruchika Sharma
Published On 2022-12-27 12:01 GMT   |   Update On 2022-12-27 12:01 GMT
Advertisement

Mumbai: Cipla expects elevated capital expenditure on automation to continue for three more years, a senior official has said. The city-headquartered company started its investment journey on the automation front two years ago and has already been recognised for its work by multiple bodies, Geena Malhotra, the chief technology officer for the company, told PTI recently.

The World Economic Forum (WEF) has recognised one of its four manufacturing units as a 'lighthouse' project for being replicated across the world, Malhotra said, adding that the company will be implementing the same across all of its 42 plants.
"On investments, we have done both regular capital expenditure and also additional investments. We have made a good amount of investments in the last two years and will be investing for about 3-4 years more in this journey," Malhotra said.
The company, however, did not disclose the financial details of its automation spends. The journey on automation has its roots in a decision Cipla took in 2020, where it started with reimagining technology and making it more cost-effective, Malhotra said, adding that it wanted to align closely with the organisation's view of how it sees itself ten years down the line.
Advertisement
The aim at the organisation level is to "produce high-quality products which comply with sustainability goals, which are affordable and leave the planet safer", she said, adding that the 3 Rs of repeatability, reliability, and resilience are its guiding force in this journey.
It had already adopted inputs like robotics in manufacturing, but automation was one step ahead, Malhotra said, pointing out that under the new paradigm, jobs like assigning work to employees at the plant are also decided by the system.
Earlier, it used to take manual intervention to assign work for every employee in a factory, whereas now with the implementation of some solutions, there is a screen indicating who needs to do what, the tools to be used for the work, etc. This ensures a highly efficient workforce by increasing productivity, she explained.
"Our work on the automation side has helped us save power, be more sustainable and reduce greenhouse gas emissions," Malhotra said. "We have moved from being predictive to prescriptive in our automation journey and the aspiration is to be fully autonomous at the end of the investment cycle," Malhotra added.
A manufacturing facility generates a lot of data, which, if studied properly, can throw up insights which can help a great deal for a unit, she said, conceding that a lot of aspects on the technology front were new for the company.
"We hired consultants to help us hire for specialised jobs like data scientists, which was new for a pharma major like us. Simultaneously, we also invested in upskilling our existing workforce," she said.
Helping the company through the journey has been US-based company Rockwell Automation. Its regional director for the India market Dilip Sawhney said life sciences is one of the key focus areas for the company.
Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Roche gets negative EMA Committee opinion on Elevidys CMA for 3-7 year olds with Duchenne muscular dystrophy

Expert Committee Clears Ravenbhel to Begin Resmetirom Phase 3 Trial, Asks for BE Data First

Menopause relief drug: USFDA extends review period for Bayer Elinzanetant

Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimer's disease

Troikaa's Fast-Acting Paracetamol Shot Hits Regulatory Hurdle, CDSCO Panel Seeks More Data

Sanofi Sarclisa approved in EU for transplant-eligible newly diagnosed multiple myeloma

Pharma Firm Ignored Safety Gaps Before Deadly Blast, Paid Rs 32 Cr To Victims, Parliament Informed

GSK Blenrep combos approved in EU for treatment of relapsed/refractory multiple myeloma